Technology
Health
Biotechnology

Ascendis Pharma

$128.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$4.31 (3.46%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ASND and other stocks, options, ETFs, and crypto commission-free!

About

Ascendis Pharma A/S American Depositary Shares, also called Ascendis Pharma, is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. Read More The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Employees
Headquarters
Hellerup, Capital Region
Founded
2006
Market Cap
5.43B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
215.24K
High Today
$129.64
Low Today
$124.57
Open Price
$125.09
Volume
87.42K
52 Week High
$131.76
52 Week Low
$53.21

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
Europe (Non-UK)
Europe

News

Seeking AlphaMay 20

Ascendis Pharma's TransCon shows favorable safety profile in late-stage study

Preliminary data from a Phase 3 clinical trial, fliGHt, evaluating the safety and tolerability of Ascendis Pharma's (NASDAQ:ASND) TransCon Growth Hormone in patients with pediatric growth hormone deficiency previously treated with commercially available daily growth hormone therapies showed a comparable safety profile.

45
Yahoo FinanceMay 6

What You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial Health

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ascendis Pharma A/S (NASDAQ:ASND) with a market-capitalization of US$5.7b, rarely draw their attention. However, history shows that overlooked mid-cap companies have performed better on a risk-adjusted manner than the smaller and larger segment of the market. Today we will look at ASND’s fin...

78
Seeking AlphaApr 29

The Prognosis For Ascendis Pharma

Today we look at Ascendis Pharma, a company based outside the United States which does not get a whole lot of analyst coverage despite an over $5 billion market capitalization.

237

Earnings

-$1.25
-$0.85
-$0.44
-$0.04
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.85 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.